Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | ESRRG | P62508 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.38 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15328453 | 0.85 | MEN1 (0.50) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL1845384 | 0.84 | MEN1 (0.46) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL17094907 | 0.84 | POLB (0.58) | MEN1KMT2ALMNANPC1RAB9A | |
| SCHEMBL356816 | 0.83 | MEN1 (0.51) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL18527956 | 0.83 | MEN1 (0.51) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL8773482 | 0.82 | MEN1 (0.69) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL395409 | 0.82 | MEN1 (0.51) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL4678735 | 0.81 | FDPS (0.38) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL23116262 | 0.81 | MEN1 (0.51) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL1684422 | 0.81 | MEN1 (0.55) | MEN1KMT2AHTTL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541023-B2 | Compounds and compositions for the treatment of neurodegenerative and inflammatory diseases | SARBONNE UNIVERSITE (FR) | 2023-01-03 | — | — | US | disclosed |
| EP-3752138-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | UNIV SORBONNE (FR) | 2022-02-09 | — | — | EP | disclosed |
| CN-113301920-A | Complexes comprising ligands, spacers, peptide linkers and biomolecules | 安斯泰来制药株式会社 | 2021-08-24 | — | — | CN | disclosed |
| CN-113271973-A | Complex comprising a ligand and a CEACAM5 antibody Fab fragment | 安斯泰来制药株式会社 | 2021-08-17 | — | — | CN | disclosed |
| US-20210046026-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | SORBONNE UNIVERSITE (FR) | 2021-02-18 | — | — | US | disclosed |
| EP-3752138-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | SORBONNE UNIVERSITE (FR) | 2020-12-23 | — | — | EP | disclosed |
| US-10420772-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | CELGENE CORPORATION (US) | 2019-09-24 | — | — | US | disclosed |
| WO-2019158859-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | SORBONNE UNIVERSITE (FR) | 2019-08-22 | — | — | WO | disclosed |
| EP-3464312-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | Celgene Corporation (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20180280399-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORP (US) | 2018-10-04 | — | — | US | disclosed |
| WO-2001047919-A9 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER AG (DE) | 2002-12-19 | — | — | WO | disclosed |
| EP-1261606-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | Bayer Aktiengesellschaft (DE) | 2002-12-04 | — | — | EP | disclosed |
| EP-1202988-A2 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-05-08 | — | — | EP | disclosed |
| WO-2002014320-A2 | NOVEL SUBSTITUTED DIARYL AZEPINE DERIVATIVES AS INTEGRIN LIGANDS | BASF AKTIENGESELLSCHAFT (DE) | 2002-02-21 | — | — | WO | disclosed |
| EP-1171435-A2 | PYRIMIDINE-2-ONE DERIVATIVES AS INTEGRIN RECEPTOR LIGANDS | BASF AKTIENGESELLSCHAFT (DE) | 2002-01-16 | — | — | EP | disclosed |
| WO-2001096312-A1 | INTEGRIN LIGANDS | BASF AKTIENGESELLSCHAFT (DE) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001093840-A2 | LIGANDS OF INTEGRIN RECEPTORS | BASF AG (DE) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001047919-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-05 | — | — | WO | disclosed |
| WO-2001010847-A2 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-02-15 | — | — | WO | disclosed |
| WO-2000061551-A2 | PYRIMIDINE-2-ONE DERIVATIVES AS INTEGRIN RECEPTOR LIGANDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280399-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | TPMT, TYMP, ATIC | MEN1 1965/4885KMT2A 1818/4885HTT 2579/4885 |
| US-11541023-B2 | Compounds and compositions for the treatment of neurodegenerative and inflammatory diseases | KLKB1, KLK5, KLK1 | MEN1 2415/4885KMT2A 1092/4885HTT 47/4885 |
| US-20210046026-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | KLKB1, KLK5, KLK1 | MEN1 2415/4885KMT2A 1092/4885HTT 47/4885 |
| US-10420772-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | TPMT, TYMP, ATIC | MEN1 1965/4885KMT2A 1818/4885HTT 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.